Whitehead, Affymetrix Start Standardization Study; Aim to Get Microarrays Ready for Clinic | GenomeWeb

While microarray-based gene expression profiling has yielded promising results for diagnosis of certain cancers, the motley assembly of array technologies is hardly ready for the prime time clinical setting: There is as yet no standard protocol or platform for conducting these experiments that could be reproducibly and consistently repeated in the clinic, and in most cases researchers haven’t even agreed on the expression profiles that signal particular cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.